Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617115 | 0.94 | ACHE (0.48) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13617105 | 0.88 | ACHE (0.44) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12707804 | 0.85 | ACHE (0.47) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12231932 | 0.85 | ACHE (0.61) | ACHEEPHX1 | |
| SCHEMBL12390787 | 0.85 | ACHE (0.46) | ACHEKMT2A | |
| SCHEMBL21068069 | 0.83 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7570219 | 0.83 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL26192228 | 0.83 | ACHE (0.59) | ACHE | |
| SCHEMBL12734631 | 0.82 | EPHX1 (0.55) | ACHEKMT2AEPHX1 | |
| SCHEMBL5012046 | 0.81 | ACHE (0.49) | ACHEHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232017-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160158253-A1 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE | MERCK PATENT GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160045522-A1 | Treatment of Cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005263-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140171389-A1 | METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140072624-A1 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130296273-A1 | TREATMENT OF BLOOD CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005263-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER | CHEK1, CHEK2, HIF1AN | ACHE 4782/4885HDAC3 654/4885HDAC4 848/4885 |
| US-20160045522-A1 | Treatment of Cancer | HIF1AN, HIF1A, EGLN3 | ACHE 2246/4885HDAC3 722/4885HDAC4 106/4885 |
| US-20160158253-A1 | TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE | HIF1AN, HIF1A, RNASE1 | ACHE 4013/4885HDAC3 669/4885HDAC4 680/4885 |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | HIF1AN, HIF1A, MTOR | ACHE 4873/4885HDAC3 100/4885HDAC4 70/4885 |
| US-20140171389-A1 | METHODS FOR TREATING CANCER | HIF1AN, HYOU1, HIF1A | ACHE 4841/4885HDAC3 504/4885HDAC4 940/4885 |
| US-20140072624-A1 | UNIT DOSE FORM FOR ORAL ADMINISTRATION | HIF1AN, HIF1A, HYOU1 | ACHE 4772/4885HDAC3 897/4885HDAC4 730/4885 |
| US-20170232017-A1 | TREATMENT OF CANCER | HIF1AN, HIF1A, EGLN3 | ACHE 2246/4885HDAC3 722/4885HDAC4 106/4885 |
| US-20130296273-A1 | TREATMENT OF BLOOD CANCER | HIF1AN, HIF1A, MCL1 | ACHE 4820/4885HDAC3 216/4885HDAC4 584/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | ACHE 4749/4885HDAC3 1100/4885HDAC4 547/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | ACHE 4749/4885HDAC3 1100/4885HDAC4 547/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | ACHE 887/4885HDAC3 1196/4885HDAC4 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.